1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The ARPA-H RAPID (Rare Disease AI/ML for Precision Integrated Diagnostics) program aims to transform the diagnosis of rare and ultra-rare diseases by developing highly accurate AI-based detection models. Rare diseases collectively affect over 350 million people globally, including approximately one in ten Americans, yet patients experience diagnostic journeys averaging six years, sometimes extending decades.
About half of individuals remain undiagnosed or misdiagnosed due to overlapping symptoms, low disease incidence, and limited specialist access.
RAPID is a two-phase effort spanning 54 months that invites proposals across three technical areas: massive-scale rare disease data collection to build the largest curated dataset of longitudinal rare disease patient data; discovery of novel diagnostic indicators using AI/ML; and a sustainable platform for development and evaluation of AI-driven diagnostic tools.
The program develops both provider-facing tools that integrate into existing clinical workflows and direct-to-patient systems enabling remote deployment for home-based disease detection, prioritizing data interoperability throughout.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Rare Disease AI/ML for Precision Integrated Diagnostics What if we could end the rare disease diagnostic odyssey? Collectively, rare diseases are far from rare — more than 10,000 unique conditions affect over 350 million people worldwide, including one in ten Americans. The lengthy diagnostic “odyssey” endured by patients with a rare disease lasts six years on average but can extend for decades.
Diagnostic delays stem from multiple factors, including overlapping symptoms, low disease incidence, and limited specialist expertise. It's estimated that half of all individuals with a rare disease remain undiagnosed or misdiagnosed, leading to inappropriate care, irreversible disease progression, and rising medical costs.
The Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) program aims to transform the diagnosis of rare and ultra-rare diseases by developing highly accurate AI-based detection models. RAPID seeks to develop provider-facing tools that prioritize data interoperability and integration into existing clinical workflows, ensuring scalability across health care organizations.
RAPID will also design cost effective, direct-to-patient systems that can be remotely deployed to help individuals and their families detect rare diseases at home or in non-clinical settings and route them toward appropriate medical support.
To catalyze model development, RAPID aims to integrate data from a fragmented landscape, building the largest curated dataset of longitudinal rare disease patient data that is optimized for training and benchmarking advanced diagnostic algorithms. If successful, RAPID will expand access to rare disease expertise and help patients and health care providers reach an accurate diagnosis in a fraction of the time it takes today.
RAPID leverages ARPA-H's ability to catalyze innovation in underserved areas like rare disease diagnosis. ARPA-H launches program to accelerate rare disease diagnosis
According to the current listing, eligibility includes: Academic institutions, non-profits, corporate entities, or combinations thereof. ARPA-H anticipates teaming will be necessary across technical areas. Proposers should have expertise in AI/ML, rare disease clinical data, diagnostic tool development, or health data infrastructure. U.S.-based and international organizations eligible to receive ARPA-H funding. Confirm the full requirements in the official notice before applying.
The current listing shows multi-year program spanning 54 months (4.5 years) with multiple awards anticipated. Individual award amounts depend on proposal scope and technical area. ARPA-H programs typically fund awards ranging from $5 million to $50 million per performer team. Total program funding not publicly disclosed but consistent with ARPA-H's overall $1.5+ billion annual budget. Verify award ceilings, matching requirements, and allowable costs in the official notice.
ARPA-H RAPID Rare Disease AI/ML for Precision Integrated Diagnostics Program is funded by Advanced Research Projects Agency for Health (ARPA-H). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Violence Against Women Discretionary Grants for Indian Tribal Governments is sponsored by Department of Justice. To increase tribal capacity to respond to violent crimes against Indian women, and to develop and strengthen victim services in cases involving violent crimes against Indian women. This listing is currently active. Program number: 16.587. Last updated on 2024-11-26.
The NSF CISE Future Computing Research (Future CoRe) program supports research in computing and communication foundations, intelligent systems, and network systems. The program funds innovative research that advances the frontiers of computing including artificial intelligence, machine learning, computer vision, natural language processing, and robotics. This is one of NSF's largest computing research programs with $280 million in total budget. Projects can address fundamental computing challenges, novel AI architectures, scalable intelligent systems, and next-generation network infrastructure.
The Emerging Health Innovators solicitation drops on SAM.gov by the end of September 2026 with 16 named topic areas, an eight-year terminal-degree ceiling, and an eligibility screen that bars national labs, FFRDCs, UARCs, and anyone who has ever led an ARPA prime award. Proposers' Day is October 13. Here is how to read the design.
Read articleARPA-H's 2026 SBIR/STTR BAA opens seven transformative health topics with $600K Phase I and $3.5M Phase II contracts — non-dilutive, milestone-driven money. The July 10 Solution Summary gate decides who ever gets to pitch. Here's how the ARPA-H model differs from NIH and how small health-tech firms actually get through the funnel.
Read articleARPA-H's FY2026 SBIR/STTR solicitation closes its Solution Summary stage July 10, with seven named topics spanning women's health, autoimmune diagnostics, toxin removal, and neurosurgical robotics. Awards run up to $600K for Phase I and $3.5M for Phase II — but they are contracts, not grants, and the four-to-six-page summary is the gate that filters out most applicants. Here is how ARPA-H's model actually works and how to win the first stage.
Read article